Thiazolidinediones (TZDs) are peroxisome proliferator‐activated receptor (PPAR)‐γ
agonists commonly used as insulin‐sensitizing drugs for the treatment of type 2 diabetes. In …

Rosiglitazone is a commonly prescribed insulin‐sensitizing drug with a selective agonistic
activity on the peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ). PPAR‐γ can …

Background and Purpose Microglial phenotype and phagocytic activity are deregulated in
Parkinson's disease (PD). PPARγ agonists are neuroprotective in experimental PD, but their …

Parkinson's disease (PD) is amongst the most frequent neurodegenerative disorders, the
main pathologic hallmark of which is the degeneration of the substantia nigra pars …

Welcome to this special issue of PPAR Research dedicated to “PPARs in
Neuroinflammation.” The central nervous system (CNS) was once thought to be an immune …

Introduction: Current treatment of Parkinson's disease (PD) is limited to symptomatic
dopaminergic therapy, while no interventions have been shown to slow down disease …

A dysregulated response of the neuroimmune system is a main contributor to the
progression of neurodegeneration in Parkinson's disease (PD). Recent findings suggest that …

Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized
by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) …

BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear
hormone receptor that has been shown to have anti-inflammatory and matrix …

Evidence suggests inflammation, mitochondria dysfunction, and oxidative stress play major
roles in Parkinson's disease (PD), where the primary pathology is the significant loss of …